Related Experiment Video
Updated: Sep 13, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
Making fertility preservation happen for the transgender community
Suset Rodriguez1, Pasquale Patrizio1
1University of Miami Miller School of Medicine, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Sciences, Miami, FL, USA.
Abstract:
Transgender individuals, whose gender identity differs from their assigned sex at birth, may undergo gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) to alleviate gender dysphoria. These treatments often impact future reproductive potential, necessitating fertility preservation (FP) discussions. Healthcare guidelines from the American Society of Reproductive Medicine (ASRM), World Professional Association for Transgender Health (WPATH), and the Endocrine Society recommend counseling on FP options, which include oocyte, sperm, and embryo cryopreservation. Challenges remain, including the impact of gender dysphoria during FP processes, the recommended length of being off hormonal treatments, the financial burden, and limited data on future pregnancy outcomes. This chapter explores FP options for transgender individuals, including those with ovaries or testes, and addresses challenges to utilization.
Related Concept Videos
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of...
Infertility in Males
Birth Control Methods
In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Spermatogenesis

